Advice
in the absence of a submission from the holder of the marketing authorisation:
denosumab (Xgeva®) is not recommended for use within NHSScotland.
Indication under review: Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with haematological malignancies involving bone.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice88KB (PDF)
Medicine details
- Medicine name:
- denosumab (Xgeva)
- SMC ID:
- SMC2110
- Indication:
prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with haematological malignancies involving bone.
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 13 August 2018